02 pH 6.87 (±0.11) 7.26 (±0.11)

<0.01 Rate of Bleeding (RBC/hr) 4 (±1.5) 3 (±1.7) 0.03 Time to rFVIIa (hr) 3.7 (±2.2) 6.2 (4.5) 0.04 rFVIIa Dose (ug/Kg) 89 (±43) 116 (±79) 0.14 > 1 rFVIIa doses (%) 9 33 0.05 Values are presented as mean (±SD) or median (IQR – Interquartile Range) when appropriate. ISS, injury severity score; AIS, abbreviated injury scale; INR, international normalized ratio; RBC/hr, units of red blood cells per hour in the first 6 hrs of admission; Statistical significance was set at p<0.05 A comparison of mortality between the two groups is shown in Table 2. Of the 11 severely acidotic (pH ≤ 7.02) patients in the last resort group, all (100%) died. Of the 60 less acidotic (pH > 7.02) patients in the

non-last resort group, 26 (43%) died. Table 2 pH selleck chemicals & In-hospital Mortality   Alive Dead Hospital Mortality pH > 7.02 (n=60) 34 26 43% pH ≤ 7.02 (n=11) 0 11 100% Sensitivity 100% (34/34) Specificity 30% (11/37) (PPV) 57% (34/60) (NPV) 100% (11/11) PPV, positive predictive value; NPV, negative predictive value AZD3965 The vast majority, 72% of rFVIIa-treated patients received only 1 dose, while 24% received 2 doses, and 4% received 3 doses after being admitted to the hospital. The first dose was administered after a median time interval of 4.5h (2.7, 7.7). Repeated doses were administered after an average time interval of 2.3h. This indicated that as the patient’s condition learn more deteriorated, more doses of rFVIIa were administered in an expedited fashion. The median initial dose was 85.7µg/kg (61.6, 102.8). This was also the overall median dosage, as most patients only received 1 dose. Of note, a transfusion medicine specialist at SHSC approved the use of rFVIIa as a final alternative when all potential interventions

failed. In the years 2000 and 2001, low doses of 17.1µg/kg of rFVIIa were administered after patients received more than 20 units of RBCs. However, following a supportive randomized control trial on rFVIIa in trauma [8], fewer units of RBCs were noted to be transfused prior to rFVIIa administration and more doses of rFVIIa were given from 2002 onwards. The total cost of administrating sufficient doses of rFVIIa to the 11 patients as a last resort was approximately $75,162 (CA). This monetary cost was measured Phosphoprotein phosphatase solely based on the amounts of doses of rFVIIa given and excluded other expenditures associated with the administration of the drug. In the United States of America, a low dose (1,200 µg or 17.1µg/kg on a 70 kg average adult) of rFVIIa is the smallest available unit dose that costs approximately the same as 8 units of plasma [23]. The price of one unit of plasma is approximately $120 (USD), including expenditures related to administering them [23]. Discussion Over the last decade, rFVIIa has been explored as a potential treatment for many coagulopathic states other than congenital conditions and hemophilias [7, 11, 24] .